Malaria Clinical Trial
Official title:
Comparison of NF54, NF135 and NF166 Strains of Plasmodium Falciparum in a Controlled Human Malaria Infection (TIP3)
An effective vaccine against malaria is urgently needed to combat the scourge of this
disease. Before candidate vaccines can be tested in endemic countries, they are first tested
in human volunteers in so-called Controlled Human Malaria Infections (CHMI's). Ideally, a
candidate vaccine should be tested against multiple strains of malaria, representative of
the disease's global distribution. To date, however, only one such strain (NF54) has been
broadly used in CHMI's.
The purpose of this study is to compare the course of infections with 2 novel malaria
strains to those with NF54 in human volunteers.
Plasmodium falciparum (Pf) malaria remains responsible for an intolerable burden of
morbidity worldwide and an effective vaccine is sorely needed to aid control efforts. Before
candidate malaria vaccines can enter full-scale (phase IIb) field trials in endemic areas,
they must first be tested under controlled circumstances in (phase IIa) clinical human
malaria infection studies. Since Pf isolates display a wide genetic diversity across the
globe, phase IIa challenge infections should be conducted with both homologous and
heterologous strains.
Since 1998 a highly successful Controlled Human Malaria Infection model at the UMC St
Radboud, Nijmegen, The Netherlands, has been employed both to test candidate vaccines and to
answer fundamental questions about pathophysiological and immunological mechanisms during
early Pf infection in human volunteers. To date largely the NF54 strain of P. falciparum has
been used in this Nijmegen model, with which extensive experience has meanwhile been
acquired. In order to increase the portfolio of Pf strains available for future phase IIa
studies, it is first necessary to document in detail the parasitological, clinical and
immunological characteristics of new candidate strains during a controlled human malaria
infection. In this study, the strains NF135 and NF166 will be compared in this regard with
the well-characterised NF54 strain.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
| Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
| Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
| Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
| Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
| Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
| Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
| Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
| Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
| Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
| Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
| Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
| Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
| Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
| Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
| Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
| Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
| Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
| Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
| Completed |
NCT02315690 -
Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland
|
Phase 3 |